Overview

TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer

Status:
Completed

Trial end date:
2005-01-01

Target enrollment:

Participant gender:

Summary

This is a dose-ranging, open label, Phase 1-2a study of TLK286 in combination with Paraplatin (carboplatin) in patients with recurrent ovarian cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Telik

Treatments:

Carboplatin